A Phase 2, randomized, double-blind, placebo-controlled multi-center trial sub-study for the clinical effects of paridiprubart treatment in hospitalized critically ill patients with COVID-19 ARDS

Blair Gordon, Fiona Allum, Michael Brooks, Nishani Rajakulendran, Emmanouil Rampakakis, John Sampalis, EB05 Study Investigators
doi: https://doi.org/10.1101/2023.09.21.23295853

Article Information

doi 
https://doi.org/10.1101/2023.09.21.23295853
History 
  • September 27, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Blair Gordon1,
  2. Fiona Allum2,
  3. Michael Brooks1,
  4. Nishani Rajakulendran1,
  5. Emmanouil Rampakakis2,3,
  6. John Sampalis2,3,*,
  7. EB05 Study Investigators4
  1. 1Edesa Biotech Inc, Markham, Ontario, Canada
  2. 2JSS Medical Research Inc, St-Laurent, Quebec, Canada
  3. 3Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada
  4. 4A list of complete EB05 Study Investigators is shown in the Acknowledgments
  1. ↵* Corresponding author; email: jsampalis{at}jssresearch.com
Back to top
Posted September 27, 2023.
Download PDF
Data/Code
Email
A Phase 2, randomized, double-blind, placebo-controlled multi-center trial sub-study for the clinical effects of paridiprubart treatment in hospitalized critically ill patients with COVID-19 ARDS
Blair Gordon, Fiona Allum, Michael Brooks, Nishani Rajakulendran, Emmanouil Rampakakis, John Sampalis, EB05 Study Investigators
medRxiv 2023.09.21.23295853; doi: https://doi.org/10.1101/2023.09.21.23295853
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area